Thioctamer, a nanoconjugate of glatiramer acetate (GA) and thioctic acid (TA), e.g. in the form of nanospheres, is provided as are compositions comprising thioctamer and methods of using the same for wound healing. Application of thioctamer to a wound accelerates wound healing, compared to control wounds that are not treated with the copolymer.

A method of inducing cell death in a subject includes administering to the subject a plurality of cell targeted nanobubbles that are internalized by the target cell and insonating nanobubbles internalized into the target cell with ultrasound energy effective to promote inertial cavitation of the internalized nanobubbles and apoptosis and/or necrosis of the target cell.

Compositions or an assembly of a series of biomimetic compounds include chemical structures that mimic or structurally resemble a nucleic acid base pair. Complexes of nanotubes and agents are useful to deliver agents into the cells or bodily tissues of individuals for therapeutic and diagnostic purposes. Exemplary compounds include those of Formula (I), (III), (V) or (VII), or of Formula (II), (IV), (VI) or (VIII). ##STR00001##

The present invention provides a non-invasive near-infrared light-controlled nanomaterial for the treatment of diabetes and use of an upconversion fluorescent nanomaterial in the preparation of a tool for the treatment of diabetes, wherein the upconversion fluorescent nanomaterial includes an inorganic nanomaterial doped with rare earth elements, and a layer of water-soluble polymer and molecules targeting liver cells, which is on the surface of the nanomaterial. In the treatment of diabetes, there is no need to surgically implant invasive optical fibers in animals, and the upconversion nanomaterial in an organism is excited by near-infrared light with high tissue penetrability. The upconversion material converts the light of near-infrared band into visible light, to activate light-sensitive proteins. This enables the remote control of intracellular glucose metabolism-related signaling pathways independent of insulin with high temporal-spatial resolution, to promote the glycogen synthesis, inhibit the gluconeogenesis, and lower the blood glucose level.

The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.

The present invention provides, among other things, methods of formulating nucleic acid-containing nanoparticles with an enzyme to afford efficient delivery of payload to a cell or tissue of interest via subcutaneous administration. In some embodiments, the present invention provides a process in which mRNA-loaded lipid nanoparticles are co-mixed with various amounts of hyaluronidase and administered via subcutaneous administration. The resulting payload can be efficiently delivered to the liver and other organs or tissues of a treated subject.

The present invention relates to a biocompatible polydopamine nanomotor capable of infiltrating a bladder wall in a biological environment and remaining inside a bladder for a long time.

The present disclosure provides a gene editing nanocapsule and a preparation method and use thereof. The gene editing nanocapsule has a core-shell structure, wherein the inner core includes a Cas/sgRNA ribonucleoprotein complex, and the outer shell includes a polymer, the Cas/sgRNA ribonucleoprotein complex has a gene editing function, and the polymer acts as a carrier for the Cas/sgRNA ribonucleoprotein complex and protects it, because the polymer contains tumor microenvironment sensitive molecules, the nanocapsules can be efficiently released in tumor cells. Further, the surface of the outer shell can be modified with a targeting agent, so that the nanocapsule can specifically target tumor cells, which improves the endocytosis efficiency of the nanocapsule. The gene editing nanocapsule has good biocompatibility and biosafety, and is expected to become a safe and efficient gene therapy drug for tumors.

The present disclosure relates to nanoparticles for delivering a drug targeting brain cancer, whose surface is modified with a peptide for targeting brain cancer, a preparation method thereof, and a use thereof, and more particularly, to nanoparticles for delivering a drug targeting brain cancer, including porous silicon nanoparticles encapsulating an anticancer drug and a peptide with an ability to target brain cancer cells bound to the surface of the nanoparticles, a preparation method thereof, and a use thereof. The nanoparticles according to the present disclosure can be used as an effective drug delivery system for treating glioblastoma by allowing a conventional anticancer agent exhibiting low tissue specificity and solubility to be specifically delivered to glioblastoma in which a caveolin receptor is overexpressed through the blood-brain barrier to induce a more efficient glioblastoma therapeutic effect.